<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236571/" ref="ordinalpos=4317&amp;ncbi_uid=3731664&amp;link_uid=PMC3236571" image-link="/pmc/articles/PMC3236571/figure/fig07/" class="imagepopup">Figure 7.  From: TRAIL receptor <span class="highlight" style="background-color:">signaling</span> and therapeutic option in bone tumors: the trap of the bone microenvironment. </a></div><br /><div class="p4l_captionBody">Resistance mechanisms in the TRAIL signaling pathway. Numerous resistance mechanisms developed by cancer cells have been described at different levels of the intrinsic and extrinsic TRAIL signaling pathways. DcRs: Decoy Receptors, DD: Death Domain, DED: Death Effector Domains, FADD: Fas-Associated protein with Death Domain, c-FLIP: cellular FLICE-inhibitory Protein, Bid: BH3-interacting domain death agonist, BCL-Xl: BCL-extra large, MCL1: Myeloid cell leukemia sequence 1, IAPs: inhibitors of apoptosis.</div></div>